ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Cross Below 50 Day Moving Average – What’s Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s stock price crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $84.02 and traded as low as $75.57. ProShares Ultra Nasdaq Biotechnology shares last traded at $77.7580, with a volume of 9,500 shares changing hands.

ProShares Ultra Nasdaq Biotechnology Trading Up 0.9%

The firm has a market cap of $81.65 million, a price-to-earnings ratio of 20.68 and a beta of 1.38. The company’s 50-day moving average is $84.02 and its 200-day moving average is $75.40.

ProShares Ultra Nasdaq Biotechnology Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Wednesday, December 24th were paid a dividend of $0.1346 per share. The ex-dividend date was Wednesday, December 24th. This represents a $0.54 annualized dividend and a yield of 0.7%.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of BIB. Franklin Resources Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth $32,000. Citadel Advisors LLC bought a new position in ProShares Ultra Nasdaq Biotechnology in the third quarter valued at about $307,000. Kaizen Financial Strategies bought a new position in ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at about $424,000. Laurel Wealth Advisors LLC raised its stake in ProShares Ultra Nasdaq Biotechnology by 4,481.0% during the second quarter. Laurel Wealth Advisors LLC now owns 13,743 shares of the exchange traded fund’s stock worth $630,000 after acquiring an additional 13,443 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new position in ProShares Ultra Nasdaq Biotechnology during the third quarter worth about $766,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.